Suramin is one of the oldest drugs in use today. It is still the treatment of choice for the hemolymphatic stage of African sleeping sickness caused by Trypanosoma brucei rhodesiense, and it is also used for surra in camels caused by Trypanosoma evansi. Yet despite one hundred years of use, suramin's mode of action is not fully understood. Suramin is a polypharmacological molecule that inhibits diverse proteins. Here we demonstrate that a DNA helicase of the pontin/ruvB-like 1 family, termed T. brucei RuvBL1, is involved in suramin resistance in African trypanosomes. Bloodstream-form T. b. rhodesiense under long-term selection for suramin resistance acquired a homozygous point mutation, isoleucine-312 to valine, close to the ATP binding site of T. brucei RuvBL1. The introduction of this missense mutation, by reverse genetics, into drug-sensitive trypanosomes significantly decreased their sensitivity to suramin. Intriguingly, the corresponding residue of T. evansi RuvBL1 was found mutated in a suramin-resistant field isolate, in that case to a leucine. RuvBL1 (Tb927.4.1270) is predicted to build a heterohexameric complex with RuvBL2 (Tb927.4.2000). RNAi-mediated silencing of gene expression of either T. brucei RuvBL1 or RuvBL2 caused cell death within 72 h. At 36 h after induction of RNAi, bloodstream-form trypanosomes exhibited a cytokinesis defect resulting in the accumulation of cells with two nuclei and two or more kinetoplasts. Taken together, these data indicate that RuvBL1 DNA helicase is involved in suramin action in African trypanosomes.
- MeSH
- DNA-helikasy genetika MeSH
- suramin farmakologie terapeutické užití MeSH
- Trypanosoma brucei brucei * genetika MeSH
- Trypanosoma brucei rhodesiense genetika MeSH
- Trypanosoma * genetika MeSH
- trypanozomóza africká * farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Trypanosoma brucei, a protist responsible for human African trypanosomiasis (sleeping sickness), is transmitted by the tsetse fly where the procyclic forms of the parasite develop in the proline-rich (1-2 mM) and glucose-depleted digestive tract. Proline is essential for the midgut colonization of the parasite in the insect vector, however other carbon sources could be available and used to feed its central metabolism. Here we show that procyclic trypanosomes can consume and metabolize metabolic intermediates, including those excreted from glucose catabolism (succinate, alanine and pyruvate), with the exception of acetate, which is the ultimate end-product excreted by the parasite. Among the tested metabolites, tricarboxylic acid (TCA) cycle intermediates (succinate, malate and α-ketoglutarate) stimulated growth of the parasite in the presence of 2 mM proline. The pathways used for their metabolism were mapped by proton-NMR metabolic profiling and phenotypic analyses of thirteen RNAi and/or null mutants affecting central carbon metabolism. We showed that (i) malate is converted to succinate by both the reducing and oxidative branches of the TCA cycle, which demonstrates that procyclic trypanosomes can use the full TCA cycle, (ii) the enormous rate of α-ketoglutarate consumption (15-times higher than glucose) is possible thanks to the balanced production and consumption of NADH at the substrate level and (iii) α-ketoglutarate is toxic for trypanosomes if not appropriately metabolized as observed for an α-ketoglutarate dehydrogenase null mutant. In addition, epimastigotes produced from procyclics upon overexpression of RBP6 showed a growth defect in the presence of 2 mM proline, which is rescued by α-ketoglutarate, suggesting that physiological amounts of proline are not sufficient per se for the development of trypanosomes in the fly. In conclusion, these data show that trypanosomes can metabolize multiple metabolites, in addition to proline, which allows them to confront challenging environments in the fly.
- MeSH
- citrátový cyklus účinky léků MeSH
- glukosa metabolismus MeSH
- hmyz - vektory parazitologie MeSH
- moucha tse-tse účinky léků parazitologie MeSH
- oxidace-redukce účinky léků MeSH
- prolin metabolismus farmakologie MeSH
- RNA interference fyziologie MeSH
- Trypanosoma brucei brucei účinky léků metabolismus MeSH
- Trypanosoma účinky léků metabolismus MeSH
- trypanozomóza africká farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Livestock diseases caused by Trypanosoma congolense, T. vivax and T. brucei, collectively known as nagana, are responsible for billions of dollars in lost food production annually. There is an urgent need for novel therapeutics. Encouragingly, promising antitrypanosomal benzoxaboroles are under veterinary development. Here, we show that the most efficacious subclass of these compounds are prodrugs activated by trypanosome serine carboxypeptidases (CBPs). Drug-resistance to a development candidate, AN11736, emerged readily in T. brucei, due to partial deletion within the locus containing three tandem copies of the CBP genes. T. congolense parasites, which possess a larger array of related CBPs, also developed resistance to AN11736 through deletion within the locus. A genome-scale screen in T. brucei confirmed CBP loss-of-function as the primary mechanism of resistance and CRISPR-Cas9 editing proved that partial deletion within the locus was sufficient to confer resistance. CBP re-expression in either T. brucei or T. congolense AN11736-resistant lines restored drug-susceptibility. CBPs act by cleaving the benzoxaborole AN11736 to a carboxylic acid derivative, revealing a prodrug activation mechanism. Loss of CBP activity results in massive reduction in net uptake of AN11736, indicating that entry is facilitated by the concentration gradient created by prodrug metabolism.
- MeSH
- dobytek MeSH
- karboxypeptidasy metabolismus MeSH
- kyseliny karboxylové metabolismus MeSH
- léková rezistence MeSH
- myši MeSH
- parazitemie veterinární MeSH
- prekurzory léčiv metabolismus MeSH
- protozoální proteiny metabolismus MeSH
- sloučeniny boru metabolismus MeSH
- trypanocidální látky metabolismus MeSH
- Trypanosoma brucei brucei účinky léků enzymologie MeSH
- Trypanosoma congolense účinky léků enzymologie MeSH
- Trypanosoma vivax účinky léků enzymologie MeSH
- trypanozomóza africká farmakoterapie parazitologie veterinární MeSH
- valin analogy a deriváty metabolismus MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2's unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting cross-resistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.
- MeSH
- akvaporin 2 * chemie genetika metabolismus MeSH
- akvaporiny chemie genetika metabolismus MeSH
- léková rezistence účinky léků genetika MeSH
- melarsoprol farmakologie MeSH
- mutace MeSH
- pentamidin farmakologie MeSH
- trypanocidální látky farmakologie MeSH
- Trypanosoma brucei brucei * účinky léků genetika metabolismus MeSH
- trypanozomóza africká farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- MeSH
- farmakoterapie metody MeSH
- lidé MeSH
- přenos infekční nemoci MeSH
- trypanozomóza africká * epidemiologie farmakoterapie přenos MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- novinové články MeSH
- zprávy MeSH
- Geografické názvy
- Kongo MeSH
- MeSH
- amébiáza diagnóza etiologie terapie MeSH
- antibakteriální látky terapeutické užití MeSH
- cysticerkóza diagnóza etiologie terapie MeSH
- dengue diagnóza etiologie terapie MeSH
- dermatitida diagnóza etiologie farmakoterapie MeSH
- dermatologie metody MeSH
- diferenciální diagnóza MeSH
- dítě MeSH
- dospělí MeSH
- drakunkulóza diagnóza etiologie terapie MeSH
- erytém diagnóza etiologie terapie MeSH
- farmakoterapie metody využití MeSH
- filarióza diagnóza etiologie farmakoterapie MeSH
- Hydrozoa patogenita MeSH
- intertrigo etiologie komplikace MeSH
- korálnatci patogenita MeSH
- kousnutí a bodnutí etiologie farmakoterapie komplikace MeSH
- kousnutí pavoukem diagnóza etiologie terapie MeSH
- larva migrans diagnóza farmakoterapie přenos MeSH
- leishmanióza diagnóza etiologie klasifikace MeSH
- lidé MeSH
- myiáza diagnóza etiologie terapie MeSH
- onchocerkóza oční diagnóza etiologie terapie MeSH
- parazitární nemoci diagnóza etiologie terapie MeSH
- primární prevence metody MeSH
- Scyphozoa patogenita MeSH
- Siphonaptera imunologie patogenita účinky léků MeSH
- štíři patogenita MeSH
- tropické lékařství metody MeSH
- trypanozomiáza diagnóza etiologie terapie MeSH
- trypanozomóza africká diagnóza etiologie farmakoterapie MeSH
- venerologie metody MeSH
- virové nemoci etiologie klasifikace terapie MeSH
- vřed dějiny etiologie terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
WHO technical report series ; no. 739
127 s. : il., tab. ; 20 cm
- MeSH
- epidemiologie organizace a řízení MeSH
- kontrola infekčních nemocí MeSH
- parazitologie MeSH
- socioekonomické faktory MeSH
- Trypanosoma izolace a purifikace klasifikace metabolismus patogenita růst a vývoj účinky léků MeSH
- trypanozomóza africká diagnóza farmakoterapie patofyziologie patologie MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- infekční lékařství
- NLK Publikační typ
- publikace WHO
WHO technical report series ; no. 635 FAO animal production and health paper ; no. 14
96 s. : il., tab. + 20 cm
- MeSH
- chemoprofylaxe MeSH
- epidemiologické monitorování MeSH
- imunitní dozor MeSH
- management farmakoterapie MeSH
- trypanocidální látky terapeutické užití MeSH
- Trypanosoma brucei gambiense MeSH
- Trypanosoma brucei rhodesiense MeSH
- trypanozomóza africká diagnóza epidemiologie farmakoterapie klasifikace patologie prevence a kontrola terapie MeSH
- Geografické názvy
- Afrika MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- cestovní a tropická medicína
- parazitologie
- epidemiologie
- NLK Publikační typ
- publikace WHO
I. vydání 172 stran, 16 nečíslovaných stran obrazových příloh : ilustrace, 1 mapa, portréty ; 21 cm
- MeSH
- dějiny 20. století MeSH
- farmakoterapie MeSH
- léčivé přípravky dějiny MeSH
- suramin terapeutické užití MeSH
- tropické lékařství dějiny MeSH
- trypanocidální látky terapeutické užití MeSH
- Trypanosoma MeSH
- trypanozomóza africká dějiny farmakoterapie MeSH
- Check Tag
- dějiny 20. století MeSH
- Publikační typ
- monografie MeSH
- Geografické názvy
- Afrika MeSH